Chiesi Group has launched its Biotech Center of Excellence, dedicated to developing and producing monoclonal antibodies, enzymes, and other proteins, in Parma, Italy. From the production of drug substances from mammalian cells to their transformation into drug products and final packaging, the company says that everything… Read More
The Scottish Medicines Consortium (SMC) has published final advice on two rare disease therapies. Elfabrio (pegunigalsidase alfa), a novel enzyme replacement therapy (ERT), has been approved as a treatment option for Fabry disease in adults. Also, birch bark extract gel has been approved… Read More
Chiesi Group has signed a memorandum of understanding with Karolinska Institutet (KI) to collaborate on joint efforts aimed accelerating research and development initiatives for respiratory diseases, rare diseases, diseases of prematurity, and other speciality care indications. Chiesi Group and KI will exchange ideas, expertise, and resources… Read More
Chiesi’s Lamzede (velmanase alfa) will now be funded on the NHS in England and Wales as an option for treating the non-neurological signs and symptoms of mild to moderate alpha-mannosidosis following a recommendation by the National Institute for Health and Care Excellence (NICE). The treatment must… Read More
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Elfabrio (pegunigalsidase alfa) as an option for treating Fabry disease (or alpha-galactosidase deficiency). The drug is recommended for use on the NHS under the terms of a confidential commercial agreement. Pegunigalsidase alfa… Read More
